At Mevion, we believe that accessible, efficient, and precise proton therapy can change cancer care worldwide. A powerful example of this vision is unfolding at Tongji Hospital in Wuhan, China, where a Mevion system has already treated its 200th patient in just eight months of operation. The rapid adoption at Tongji Hospital exemplifies this vision and demonstrates the clinical and operational advantages of Mevion’s compact technology.

Leading the Way in Advanced Cancer Care

Tongji Hospital, one of China’s premier teaching hospitals, has long been at the forefront of cancer diagnosis, treatment, and innovation. Its Oncology Department is among the earliest established in the country and serves over 6 million patients annually across its campuses. At the Optics Valley campus, a new 135,000-square-foot proton therapy center, equipped with Mevion’s compact system, the S250i, is designed for future expansion, which has catapulted the hospital into the next era of advanced, precision cancer care. The center marks a new era of advanced precision cancer treatment in China.

Since beginning treatment in December 2024, the Tongji Proton Therapy Center has quickly emerged as one of the fastest-ramping proton facilities globally and is the first and only clinically treating single-room proton therapy system in China. The Center has demonstrated extraordinary achievement that underscores both the strong demand for proton therapy and the reliability of Mevion’s U.S. manufactured systems.

A Broad Impact Across Cancer Types and Ages

The 200 patients treated to date represent a diverse group:

• Central nervous system tumors (55 cases)
• Digestive system tumors (51 cases)
• Head and neck cancers (36 cases)
• Breast cancer (30 cases)
• Lung cancer (20 cases)

Patients have ranged in age, including pediatric patients, demonstrating the versatility and safety of proton therapy across populations. Importantly, Tongji has already treated 12 pediatric cases, providing life-changing access to advanced care for children facing some of the most difficult diagnoses.

Setting a New Standard for Proton Therapy Adoption

The rapid clinical adoption at Tongji is more than a milestone—it is proof that when proton therapy is delivered through compact, efficient system designs, it can quickly scale to meet patient needs.

“We congratulate the entire team at Tongji Hospital on reaching this remarkable milestone of 200 patients in just eight months,” said Dr. Tina Yu, CEO and President of Mevion Medical Systems. “This achievement demonstrates that our single-room S250i system delivers superior efficiency compared to multi-room systems, which need to share beams between treatment rooms. We achieved the fastest timeline from accelerator delivery to first patient treatment in China, and now the fastest patient volume ramp-up. This speaks to the beauty of our simplified design, low learning curve for users, and efficient beam delivery. A special thank you goes to our dedicated service engineers whose strong local presence makes this success possible—they work seamlessly on-site with the Tongji team to ensure operational excellence.”

Looking Ahead

With patients traveling from across China to seek care, the Tongji Proton Therapy Center is rapidly becoming a national destination for proton therapy. Its success demonstrates what is possible when advanced technology meets strong clinical leadership.

For Mevion, this milestone reinforces our mission: to make superior proton therapy accessible to as many patients as possible, accelerating the global advancement of cancer treatment.